Kidney and heart failure outcomes associated with SGLT2 inhibitor use

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Chronic kidney disease (CKD) and heart failure are major global health concerns with high morbidity and mortality.
• Existing pharmacological treatments have limitations in improving outcomes for these conditions.
• Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially for type 2 diabetes, showed potential cardiovascular and renal benefits.

Purpose of the Study:

• To evaluate the cardiovascular and kidney protective effects of SGLT2 inhibitors in patients with CKD or heart failure.
• To assess the consistency of these benefits across various patient subgroups.
• To investigate the safety profile of SGLT2 inhibitors in these populations.

Main Methods:

• Clinical trials were conducted to assess SGLT2 inhibitors in patients with CKD and heart failure.
• Dedicated trials focused on cardiovascular and renal outcomes.
• Post-hoc analyses examined effects on specific complications like anemia and hyperkalemia, and safety parameters.

Main Results:

• SGLT2 inhibitors demonstrated consistent benefits in cardiovascular and renal outcomes across diverse patient subgroups, including those with and without type 2 diabetes, varying CKD stages, and different heart failure types.
• In patients with CKD, SGLT2 inhibitors were found to reduce the risk of anemia and hyperkalemia.
• Safety assessments indicated that SGLT2 inhibitors are generally well-tolerated, with no increased risk of hypoglycemia or acute kidney injury in the studied populations.

Conclusions:

• SGLT2 inhibitors represent a novel and effective treatment option for patients suffering from CKD and heart failure.
• Their benefits extend to patients irrespective of diabetes status, CKD stage, or heart failure classification.
• The favorable safety profile further supports their use in managing these complex conditions.